Matthew Perrone

Read the latest stories and analysis from Matthew Perrone.

FILE - In this Tuesday, Dec. 21, 2004, file photo, several Aleve tablets appear in front of bottles of the pain reliever, in Boston. Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains. (AP Photo/Steven Senne, File)

FDA reconsiders heart safety of common pain pills

Matthew Perrone · February 10, 2014 9:36 pm

Pharma data play larger role in Olympic drug tests

Matthew Perrone · February 7, 2014 11:10 pm

This undated image provided by Given Imaging, shows the new bite-size camera to help screen patients who have trouble with colonoscopies. The Food and Drug Administration cleared the device for patients who have had trouble with the cringe-inducing colonoscopy procedure, which involves probing the large intestine with a tiny camera embedded in a four-foot long, flexible tube. (AP Photo/Given Imaging)

FDA approves pill camera to screen colon

Matthew Perrone · February 3, 2014 11:09 pm

FDA reviews safety of testosterone therapy for men

Matthew Perrone · January 31, 2014 11:24 pm

FDA: Aleve may be safer on heart than rival drugs

Matthew Perrone · January 28, 2014 10:12 pm

FDA approves diabetes drug with new approach

Matthew Perrone · January 8, 2014 6:01 pm

Feds crack down on 4 bogus weight loss aids

Matthew Perrone · January 7, 2014 8:40 pm

New drug approvals from FDA declined in 2013

Matthew Perrone · January 2, 2014 4:05 pm

FILE - This Tuesday, April 30, 2013, file photo, shows Dawn Ultra antibacterial soap in a kitchen in Chicago. The Food and Drug Administration says Monday, Dec. 16, 2013, there is no evidence that antibacterial chemicals used in liquid soaps and washes help prevent the spread of germs, and there is some evidence they may pose health risks. (AP Photo/Kiichiro Sato)

FDA: Anti-bacterial soaps may not curb bacteria

Matthew Perrone · December 16, 2013 11:07 pm

In this Friday, Sept. 27, 2013, photo, Cindy Whitehead holds a tablet of flibanserin in her office at Sprout Pharmaceuticals in Raleigh, N.C. Sprout Pharmaceuticals said Wednesday, Dec. 11, 2013, it has reached an impasse with the Food and Drug Administration over its drug, flibanserin. The daily pill is designed to increase libido in women by acting on brain chemicals linked to mood and appetite. (AP Photo/Allen G. Breed)

Female libido drug remains in limbo

Matthew Perrone · December 11, 2013 7:33 pm

FDA approves breakthrough hepatitis C drug

Matthew Perrone · December 6, 2013 10:49 pm

23andMe faces class action lawsuit in California

Matthew Perrone · December 3, 2013 10:11 pm